Industry
Biotechnology
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 2:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 10:59 am
Portfolio Pulse from Benzinga Insights
June 03, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 10:19 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 1:46 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.